Friday, March 7, 2014
ECR 2014 - SF7b - Imaging biomarkers in cancer drug development
An area where medical imaging informatics could play a major role is imaging biomarkers. The involvement of imaging informatics in this area is not only in the image processing, but also in validation, evaluation and collection of imaging data and related quantitative data using imaging biobanks.
Imaging biomarkers are currently a hot topic, in imaging this relates to:
1. size measurement based imaging biomarkers (RECIST, mRECIST and EASL)
2. functional and molecular biomarkers (perfusion, vascular function, cellularity, cell-death, metabolism, proliferation, and target specific tracers)
there are three biomarker modalities:
1. biospecimen removed from a patient
2. biosignal measured using in vivo device
3. patient reported outcomes
Important is that biomarkers require extensive validation and standardization of acquisition, evaluation, and measurement.
The validation of imaging biomarkers however, is a very hard job.
Imaging biomarkers should be used to better identify the patients most likely to benefit and to obtain better hypothosis testing.
problems in using imaging biomarkers include the variety in accquisition devices and the fact they are not designed for biomarker measurements.